impact factor, citescore
logo
 

Clinical aspects

 

Cardiopulmonary involvement in Takayasu's arteritis


1, 2, 3, 4, 5

 

  1. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. brennan.david1@mayo.edu
  2. Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
  3. Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  4. Amiens University Hospital and INSERM U-1088, Department of Internal Medicine and RECIF, Jules Verne University of Picardy, Amiens, France.
  5. Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

CER10316
2018 Vol.36, N°2 ,Suppl.111
PI 0046, PF 0050
Clinical aspects

Free to view
(click on article PDF icon to read the article)

PMID: 28628465 [PubMed]

Received: 10/02/2017
Accepted : 24/04/2017
In Press: 12/06/2017
Published: 18/05/2018

Abstract

OBJECTIVES:
To evaluate cardiopulmonary (CP) involvement in patients with Takayasu’s arteritis (TAK) and assess the impact on disease outcomes.
METHODS:
A retrospective cohort of patients with newly diagnosed TAK from 1984 to 2009 was assembled. Demographics, baseline disease characteristics, relapse events, surgeries and mortality were abstracted from direct medical record review. Angiograms, advanced imaging and cardiac studies were reviewed for evidence of CP involvement. Cox models with time-dependent covariates were used to assess the association between CP involvement and outcomes.
RESULTS:
A total of 124 patients with TAK were identified. Forty-five (36%) patients had at least one objective CP abnormality observed within 6 months of TAK diagnosis. Age at diagnosis was higher in those with CP involvement than those without (34.6 vs 30.1 yrs; p=0.04). Baseline characteristics and symptoms were similar, except shortness of breath, which was more frequently observed at TAK diagnosis in patients with CP involvement compared to those without (53% vs 21%; p=0.001). Composite CP involvement was not associated with risk of first surgery [Hazard ratio (95% CI): 1.21 (0.64-2.30); p=0.56]. However, pulmonary hypertension (PH) on echocardiogram was significantly associated with risk of first surgery [HR (95% CI): 12.9 (1.86- 89.14); p=0.01]. CP involvement was not significantly associated with mortality [HR (95% CI): 2.51 (0.45- 14.02); p=0.29].
CONCLUSIONS:
Cardiopulmonary abnormalities in TAK are common at the time of initial presentation. In this population, the presence of PH predicted a 13-fold increased risk for vascular or valvular surgery. In this cohort, the presence of CP involvement did not increase mortality.

Rheumatology Article